Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting

Pharmacogenetics Clinical Trial

Official title:

Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02937545
• Other study ID #: Pro00068552
• Secondary ID: 2R01GM081416-08A
• Status: Completed
• Phase: N/A
• Start date: February 22, 2017
• Est. completion date: September 10, 2019

Study information

• Verified date: May 2021
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to compare patient use of and satisfaction with community pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication therapy management (MTM) service. Pharmacist and patient outcome measures will be collected by surveys, interviews, and review of pharmacy records.

Description:

This study aims to investigate the delivery of pharmacogenetic (PGx) testing alone or in combination with Medication Therapy Management (MTM) in the community pharmacy setting in order to assess and compare the two delivery models. Using a clust randomized trial, these effects of these two models will be compared. Pharmacist and patient outcome measures will be collected by survey, interviews, and review of pharmacy records. The investigators intend to compare the effect of PGx alone and PGx with MTM from the pharmacy perspective (to assess impact on workflow/operations) and patient perspective (to assess acceptance of testing, understanding of results, medication adherence, and overall satisfaction with delivery model). In the PGx only arm, pharmacists will offer PGx testing to patients who are prescribed one of the 10 eligible drugs (aripiprazole, carisoprodol, celecoxib, citalopram, clopidogrel, metoprolol, nortriptyline, paroxetine, simvastatin, warfarin) and will return results to the patient and physician with any recommendations for drug or dosage changes based on results. In the PGx and MTM arm, pharmacists will offer PGx testing to patients prescribed one of the 10 eligible drugs and provide two MTM sessions: one at the time of testing, and one when results are returned. All patients will be surveyed before PGx testing and 3 months after receiving results. Pharmacists will be surveyed prior to their participation and following the conclusion of the study. Pharmacists will also conduct a chart review of patients and document all interactions with enrolled patients and their providers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 190
• Est. completion date: September 10, 2019
• Est. primary completion date: September 10, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Pharmacist participants must be community pharmacists licensed and practicing in North Carolina

• Patient participants must be prescribed one of the 10 eligible medications (aripiprazole, carisoprodol, celecoxib, citalopram, clopidogrel, metoprolol, nortriptyline, paroxetine, simvastatin, warfarin)

• Patient participants must be able to consent to participating and testing on their own, and be able to read English

Exclusion Criteria:

• Patients who have previously undergone pharmacogenetic testing will not be eligible.

Related Conditions & MeSH terms

• Pharmacogenetics

Intervention

Other:
• Medication Therapy Management
Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
• Pharmacogenetic testing
Community pharmacist will provide pharmacogenetic testing.

Locations

Country	Name	City	State
United States	Duke University	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	National Institute of General Medical Sciences (NIGMS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting	Post-Study Survey question: "Now that you know your test results, would you have taken the test in the first place?" (Response: 'would definitely' have taken the test)	Post-study Survey (after test results received)
Primary	Number of Patient Participants Who Recalled All Test Results	Post-Study Survey Question: "As best you can, please choose the result of your drug response test for the following genes" (Response: Result selected for all 5 genes)	Post-study (after test results received)
Primary	Number of Patient Participants Who Considered Time With Pharmacist to be Worthwhile	Patient survey question - "Did you feel your time spent with the pharmacist was worthwhile?". Reported as number of participants who selected answer choice "Yes, definitely".	Post-study (after test results received)
Primary	Number of Patient Participants' With High Medication Adherence	Pre-study (baseline) survey question: "In the last 7 days, I took all doses as prescribed" (Response: "strongly agree")	Baseline (prior to testing)
Primary	Number of Patient Participants With High Medication Adherence (Post-study)	Post-study (follow-up) survey question: "In the last 7 days, I took all doses as prescribed" (Response: "strongly agree")	Post-Study (after test results received)
Primary	Number of Patient Participants Who Reported Understanding of Implications of Test Results	Post_Study Survey Question: Please indicate your level of agreement with the following statement: "I understood clearly my choices for prevention or early detection of side effects." (Response: "Sometimes/Often")	Post-study (after test results received)
Secondary	Number of Pharmacist Participants Who Reported Strong Likelihood to Continue to Deliver PGx Testing	Pharmacist Post-Survey Question: How likely are you to continue providing PGx testing in your pharmacy after the conclusion of the study? (Answer response: "definitely continue")	Post-study (3 months)
Secondary	Average Score of PGx Knowledge Assessment by Pharmacist Participants	7-question knowledge assessment of pharmacogenetics. Possible Score Range 0-7; actual range 3-7 (higher scores correspond to higher number of correct answers/higher knowledge)	Baseline (prior to start of study)
Secondary	Number of Pharmacist Participants Who Reported 'Reimbursement' as Most Common Barrier to Delivery of PGx Testing	Pharmacist Post-Survey Question: Of the following potential barriers to providing PGx testing services, please indicate the greatest perceived barrier (most common response: "reimbursement")	Post-study (3 months)
Secondary	Number of Participating Pharmacists Who Feel Qualified to Deliver PGx Testing	Pharmacist Post-Study survey question: I feel qualified to provide PGx testing at my pharmacy (Answer response: "strongly agree/agree").	Post-study (3 months)